Mini-transplantation strategy for solid tumors.
In our phase I reduced-intensity stem cell transplantation (RIST) study with fludarabine (180 mg/m2) or cladribine (0.66 mg/kg) plus busulfan (8 mg/kg), with or without anti-thymocyte globulin (ATG), a total of 85 patients who had a variety of hematological (n=68) or metastatic solid tumors (n=17) were treated. This presentation will further update the results of our RIST program, highlighting several burning issues in the treatment of patients with solid tumors. Pathological classification of solid tumor in this program included renal cell carcinoma (RCC, n=8), rhabdomyosarcoma (n=2), malignant melanoma (n=2), neuroblastoma (n=2), osteosarcoma (n=1), alveolar saft-part-tumor (n=1) and cholangiocarcinoma (n=1). All received PBSCT from an HLA-identical or one antigen-mismatched relative. Regimen-related toxicities were mild and >90% donor chimerism was achieved before day 30 in a majority of patients. The overall survival for hematological and solid malignancies was the same ca. 70% at 1 year.
Takaue
Yoichi
Y
Hematopoietic Stem Cell Transplant/Immunotherapy Unit, National Cancer Center Hospital, Tokyo, Japan.
D017321:Clinical Trials, Phase I as Topic; D003131:Combined Modality Therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D009369:Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D015996:Survival Rate